We are live on ! Find out more

Recursion Pharmaceuticals

RXRX

Market cap $2.29B

3.83 USD

+0.03

0.79%

At close Updated Oct 27, 10:00 AM EDT

1 day

0.79%

5 days

4.64%

1 month

3.51%

3 months

27.24%

6 months

10.06%

Year to date

-8.81%

1 year

-39.21%

5 years

-79.68%

10 years

-87.76%

About: Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.

Employees: 600

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 24.2%

Neutral 63.6%

Negative 12.1%

Zacks Investment Research

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $3.8, signifying a +2.7% move from its prior day's close.

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3

Salt Lake City, UT, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2026 financial results on Monday, November 2, 2026, after the close of the financial markets, with live call from the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) Annual Meeting in Denver, Colorado on November 3, 2026, at 8:00 AM ET / 6:00 AM MT / 1:00 PM GMT.

Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3

Zacks Investment Research

Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing

Recursion Pharmaceuticals (RXRX) reached $3.66 at the closing of the latest trading day, reflecting a +1.39% change compared to its last close.

Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi's development pipeline, with phase 1 clinical study currently planned to begin in 2027 Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi's development pipeline, with phase 1 clinical study currently planned to begin in 2027

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock

Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today announced the pricing of an underwritten offering of 61,540,000 shares of its Class A common stock at a price of $3.25 per share. All of the shares are to be sold by Recursion.

Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock

Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone

SALT LAKE CITY, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today announced a $200 million underwritten offering of common stock with leading healthcare and institutional investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other prominent healthcare specialists and mutual funds, as well as business and clinical updates across its pipeline, including updated Phase 1b/2 data for REC-4881 in Familial Adenomatous Polyposis (FAP), promising early data in the Phase 1 DAHLIA trial for REC-1245, and a key milestone with Sanofi optioning a potential first-in-class immunology development candidate from their collaboration.

Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone

Zacks Investment Research

Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $4.01, moving 8.03% from the previous trading session.

Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note

Zacks Investment Research

Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.63, representing a -3.14% change from its previous close.

Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors

Zacks Investment Research

Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note

In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.7, indicating a -1.2% shift from the previous trading day.

Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note

Squeeze Watch: 10 Stocks With Over 33% Short Interest

Ten stocks worth more than $2 billion each have more than a third of their float sold short. At the top of the list, one company has more than 80% of its float sold short.

Squeeze Watch: 10 Stocks With Over 33% Short Interest

See News Rankings

Price charts implemented using Lightweight Charts™